Epigenetic modulations of immune cells: from normal development to tumor progression

The dysfunction of immune cell development often impairs immunological homeostasis, thus causing various human diseases. Accumulating evidence shows that the development of different immune cells from hematopoietic stem cells are highly fine-tuned by different epigenetic mechanisms including DNA methylation, histone modifications, chromatin remodeling and RNA-related regulations. Understanding how epigenetic regulators modulate normal development of immune cells contributes to the identification of new strategies for various diseases. Here, we review recent advances suggesting that epigenetic modulations can orchestrate immune cell development and functions through their impact on critical gene expression. We also discuss the aberrations of epigenetic modulations in immune cells that influence tumor progression, and the fact that underlying mechanisms affect how epigenetic drugs interfere with tumor progression in the clinic.

[1]  Tianwen Lai,et al.  METTL3-mediated m6A mRNA methylation regulates neutrophil activation through targeting TLR4 signaling. , 2023, Cell reports.

[2]  Xuetao Cao,et al.  The RNA m6A demethylase ALKBH5 drives emergency granulopoiesis and neutrophil mobilization by upregulating G-CSFR expression , 2023, Cellular & molecular immunology.

[3]  M. Dawson,et al.  Inhibition of METTL3 results in a cell-intrinsic interferon response that enhances anti-tumour immunity. , 2023, Cancer discovery.

[4]  M. Zheng,et al.  Loss of the m6A methyltransferase METTL3 in monocyte-derived macrophages ameliorates Alzheimer’s disease pathology in mice , 2023, PLoS biology.

[5]  Ling-Zu Kong,et al.  FTO negatively regulates the cytotoxic activity of natural killer cells , 2023, EMBO reports.

[6]  Zhike Lu,et al.  m6A demethylase ALKBH5 is required for antibacterial innate defense by intrinsic motivation of neutrophil migration , 2022, Signal Transduction and Targeted Therapy.

[7]  Zhirong Sun,et al.  Neutrophil extracellular traps mediate m6A modification and regulates sepsis-associated acute lung injury by activating ferroptosis in alveolar epithelial cells , 2022, International journal of biological sciences.

[8]  Rui Zhang,et al.  Mettl14-Mediated m6A Modification Is Essential for Germinal Center B Cell Response , 2022, The Journal of Immunology.

[9]  Yuanhong Xu,et al.  Dynamic regulation and functions of mRNA m6A modification , 2022, Cancer cell international.

[10]  Zuyi Weng,et al.  ALKBH5-mediated N6-methyladenosine modification of TRERNA1 promotes DLBCL proliferation via p21 downregulation , 2022, Cell Death Discovery.

[11]  D. Hanahan.  Hallmarks of Cancer: New Dimensions. , 2022, Cancer discovery.

[12]  A. Rao,et al.  TET deficiency perturbs mature B cell homeostasis and promotes oncogenesis associated with accumulation of G-quadruplex and R-loop structures , 2021, Nature immunology.

[13]  Mengwen Zhang,et al.  Pancreatic cancer cells render tumor-associated macrophages metabolically reprogrammed by a GARP and DNA methylation-mediated mechanism , 2021, Signal Transduction and Targeted Therapy.

[14]  R. Flavell,et al.  METTL3-mediated m6A RNA methylation promotes the anti-tumour immunity of natural killer cells , 2021, Nature Communications.

[15]  M. Caligiuri,et al.  The RNA m6A reader YTHDF2 controls NK cell antitumor and antiviral immunity , 2021, The Journal of experimental medicine.

[16]  Asha A. Nair,et al.  BMI1 maintains the Treg epigenomic landscape to prevent inflammatory bowel disease. , 2021, The Journal of clinical investigation.

[17]  M. Bissonnette,et al.  The loss of RNA N6-adenosine methyltransferase Mettl14 in tumor-associated macrophages promotes CD8+ T cell dysfunction and tumor growth. , 2021, Cancer cell.

[18]  Zhongping Liang,et al.  miR–9-5p regulates immunometabolic and epigenetic pathways in β-glucan–trained immunity via IDH3α , 2021, JCI insight.

[19]  R. Xiang,et al.  Cancer-derived exosomal miR-138-5p modulates polarization of tumor-associated macrophages through inhibition of KDM6B , 2021, Theranostics.

[20]  G. Bae,et al.  Protein arginine methyltransferases: promising targets for cancer therapy , 2021, Experimental & Molecular Medicine.

[21]  R. Flavell,et al.  Pooled CRISPR screening identifies m6A as a positive regulator of macrophage activation , 2021, Science Advances.

[22]  A. Samsonova,et al.  Immune modulation underpins the anti‐cancer activity of HDAC inhibitors , 2021, Molecular oncology.

[23]  Henry W. Long,et al.  EZH2 inhibition activates a dsRNA–STING–interferon stress axis that potentiates response to PD-1 checkpoint blockade in prostate cancer , 2021, Nature Cancer.

[24]  Pengyuan Yang,et al.  RNA m6A methylation orchestrates cancer growth and metastasis via macrophage reprogramming , 2021, Nature Communications.

[25]  L. Penengo,et al.  Histone Ubiquitination: An Integrative Signaling Platform in Genome Stability. , 2021, Trends in genetics : TIG.

[26]  F. He,et al.  METTL3 restrains papillary thyroid cancer progression via m6A/c-Rel/IL-8 mediated neutrophils infiltration. , 2021, Molecular Therapy.

[27]  Yun-Gui Yang,et al.  MYC promotes cancer progression by modulating m6A modifications to suppress target gene translation , 2021, EMBO reports.

[28]  Yi Yu,et al.  PBK phosphorylates MSL1 to elicit epigenetic modulation of CD276 in nasopharyngeal carcinoma , 2021, Oncogenesis.

[29]  P. Defossez,et al.  Staying true to yourself: mechanisms of DNA methylation maintenance in mammals , 2020, Nucleic acids research.

[30]  C. Xiao,et al.  Ascorbic Acid Promotes Plasma Cell Differentiation through Enhancing TET2/3-Mediated DNA Demethylation. , 2020, Cell reports.

[31]  J. Ng,et al.  The Methyltransferase DOT1L Controls Activation and Lineage Integrity in CD4+ T Cells during Infection and Inflammation. , 2020, Cell reports.

[32]  J. Cui,et al.  USP38 Couples Histone Ubiquitination and Methylation via KDM5B to Resolve Inflammation , 2020, Advanced science.

[33]  C. Arrowsmith,et al.  Identification of lysine isobutyrylation as a new histone modification mark , 2020, bioRxiv.

[34]  Yingying Cheng,et al.  The m6A Methyltransferase METTL3 Is Functionally Implicated in DLBCL Development by Regulating m6A Modification in PEDF , 2020, Frontiers in Genetics.

[35]  B. Tycko,et al.  A DNA Hypomethylating Drug Alters the Tumor Microenvironment and Improves the Effectiveness of Immune Checkpoint Inhibitors in a Mouse Model of Pancreatic Cancer , 2020, Cancer Research.

[36]  J. Ni,et al.  Expression pattern of m6A regulators is significantly correlated with malignancy and antitumor immune response of breast cancer , 2020, Cancer Gene Therapy.

[37]  Lei Wei,et al.  Analysis of N6-Methyladenosine Methyltransferase Reveals METTL14 and ZC3H13 as Tumor Suppressor Genes in Breast Cancer , 2020, Frontiers in Oncology.

[38]  M. Bissonnette,et al.  A New Model of Spontaneous Colitis in Mice Induced by Deletion of an RNA m6A Methyltransferase Component METTL14 in T Cells , 2020, Cellular and molecular gastroenterology and hepatology.

[39]  Naixin Wang,et al.  Circular RNA circSnx5 Controls Immunogenicity of Dendritic Cells through the miR-544/SOCS1 Axis and PU.1 Activity Regulation. , 2020, Molecular therapy : the journal of the American Society of Gene Therapy.

[40]  T. Kurosaki,et al.  Tet DNA demethylase is required for plasma cell differentiation by controlling expression levels of IRF4. , 2020, International immunology.

[41]  A. Melnick,et al.  TET2 deficiency reprograms the germinal center B cell epigenome and silences genes linked to lymphomagenesis , 2020, Science Advances.

[42]  Hui-Lung Sun,et al.  Control of Early B Cell Development by the RNA N6-Methyladenosine Methylation. , 2020, Cell reports.

[43]  Chun-Xiao Song,et al.  Mapping the epigenetic modifications of DNA and RNA , 2020, Protein & Cell.

[44]  Clifford A. Meyer,et al.  Hdac3 is an epigenetic inhibitor of the cytotoxicity program in CD8 T cells , 2020, The Journal of experimental medicine.

[45]  Zhiwei Wang,et al.  Dendritic cells with METTL3 gene knockdown exhibit immature properties and prolong allograft survival , 2020, Genes & Immunity.

[46]  Hongyu Zhao,et al.  Elevated serum interleukin-8 is associated with enhanced intratumor neutrophils and reduced clinical benefit of immune-checkpoint inhibitors , 2020, Nature Medicine.

[47]  Qingyuan Yang,et al.  MIR145-3p promotes autophagy and enhances bortezomib sensitivity in multiple myeloma by targeting HDAC4 , 2020, Autophagy.

[48]  K. Miyazono,et al.  Epigenetic remodelling shapes inflammatory renal cancer and neutrophil-dependent metastasis , 2020, Nature Cell Biology.

[49]  S. Weinberg,et al.  Maintenance DNA methylation is essential for regulatory T cell development and stability of suppressive function , 2020, bioRxiv.

[50]  M. Luo,et al.  Overexpression of microRNA-155 enhances the efficacy of dendritic cell vaccine against breast cancer , 2020, Oncoimmunology.

[51]  A. Shilatifard,et al.  Epigenetic modifications of histones in cancer , 2019, Genome Biology.

[52]  P. Sharma,et al.  Differences in Tumor Microenvironment Dictate T Helper Lineage Polarization and Response to Immune Checkpoint Therapy , 2019, Cell.

[53]  Tibor van Welsem,et al.  The histone methyltransferase DOT1L prevents antigen-independent differentiation and safeguards epigenetic identity of CD8+ T cells , 2019, Proceedings of the National Academy of Sciences.

[54]  Yuquan Wei,et al.  Epigenetic regulation of macrophages: from homeostasis maintenance to host defense , 2019, Cellular & Molecular Immunology.

[55]  J. Schlom,et al.  Cooperative Immune-Mediated Mechanisms of the HDAC Inhibitor Entinostat, an IL15 Superagonist, and a Cancer Vaccine Effectively Synergize as a Novel Cancer Therapy , 2019, Clinical Cancer Research.

[56]  Wanlu Liu,et al.  Epigenetic initiation of the TH17 differentiation program is promoted by Cxxc finger protein 1 , 2019, Science Advances.

[57]  Jun Wu,et al.  MicroRNA-181a Inhibits Activated B-Cell-Like Diffuse Large B-Cell Lymphoma Progression by Repressing CARD11 , 2019, Journal of oncology.

[58]  B. Ren,et al.  Metabolic regulation of gene expression by histone lactylation , 2019, Nature.

[59]  Shuai Gao,et al.  Diagnostic value of NKG2D promoter methylation in hepatitis B virus-associated hepatocellular carcinoma. , 2019, Biomarkers in medicine.

[60]  Richard D Emes,et al.  The Cross-Talk between miR-511-3p and C-Type Lectin Receptors on Dendritic Cells Affects Dendritic Cell Function , 2019, The Journal of Immunology.

[61]  Mark S. Anderson,et al.  The epigenetic regulator ATF7ip inhibits Il2 expression, regulating Th17 responses , 2019, The Journal of experimental medicine.

[62]  Dennie T. Frederick,et al.  Intratumoral Activity of the CXCR3 Chemokine System Is Required for the Efficacy of Anti-PD-1 Therapy. , 2019, Immunity.

[63]  C. Zahnow,et al.  DFMO and 5-azacytidine increase M1 macrophages in the tumor microenvironment of murine ovarian cancer. , 2019, Cancer research.

[64]  C. Glass,et al.  SF2523: Dual PI3K/BRD4 Inhibitor Blocks Tumor Immunosuppression and Promotes Adaptive Immune Responses in Cancer , 2019, Molecular Cancer Therapeutics.

[65]  Lijia Ma,et al.  Mettl3-mediated mRNA m6A methylation promotes dendritic cell activation , 2019, Nature Communications.

[66]  Libing Shen,et al.  Integrative analysis identifies DNMTs against immune-infiltrating neutrophils and dendritic cells in colorectal cancer , 2019, Epigenetics.

[67]  V. Adoue,et al.  The Histone Methyltransferase SETDB1 Controls T Helper Cell Lineage Integrity by Repressing Endogenous Retroviruses , 2019, Immunity.

[68]  T. Kurosaki,et al.  Plasma cell differentiation during the germinal center reaction , 2019, Immunological reviews.

[69]  A. Mai,et al.  The emerging role of epigenetics in human autoimmune disorders , 2019, Clinical Epigenetics.

[70]  B. Eynde.  Faculty Opinions recommendation of Anti-tumour immunity controlled through mRNA m6A methylation and YTHDF1 in dendritic cells. , 2019, Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature.

[71]  Hongjie Wang,et al.  Epigenetically modulated FOXM1 suppresses dendritic cell maturation in pancreatic cancer and colon cancer , 2019, Molecular oncology.

[72]  A. Robaszkiewicz,et al.  EP300-HDAC1-SWI/SNF functional unit defines transcription of some DNA repair enzymes during differentiation of human macrophages. , 2019, Biochimica et biophysica acta. Gene regulatory mechanisms.

[73]  Nan Li,et al.  Intracellular HSP70L1 inhibits human dendritic cell maturation by promoting suppressive H3K27me3 and H2AK119Ub1 histone modifications , 2019, Cellular & Molecular Immunology.

[74]  V. Trochon-Joseph,et al.  Enhanced anti-tumor efficacy of checkpoint inhibitors in combination with the histone deacetylase inhibitor Belinostat in a murine hepatocellular carcinoma model , 2018, Cancer Immunology, Immunotherapy.

[75]  Husheng Wang,et al.  Exosomes Released from Tumor-Associated Macrophages Transfer miRNAs That Induce a Treg/Th17 Cell Imbalance in Epithelial Ovarian Cancer , 2018, Cancer Immunology Research.

[76]  A. Akhtar,et al.  The many lives of KATs — detectors, integrators and modulators of the cellular environment , 2018, Nature Reviews Genetics.

[77]  J. Hung,et al.  USP24 induces IL-6 in tumor-associated microenvironment by stabilizing p300 and β-TrCP and promotes cancer malignancy , 2018, Nature Communications.

[78]  J. Qu,et al.  Epigenetic Modifications in Cardiovascular Aging and Diseases , 2018, Circulation research.

[79]  A. Valencia,et al.  Dynamics of Transcription Regulation in Human Bone Marrow Myeloid Differentiation to Mature Blood Neutrophils , 2018, Cell reports.

[80]  G. Freeman,et al.  BET Bromodomain Inhibition Cooperates with PD-1 Blockade to Facilitate Antitumor Response in Kras-Mutant Non–Small Cell Lung Cancer , 2018, Cancer Immunology Research.

[81]  N. Wajapeyee,et al.  Epigenetic Mechanisms Dictating Eradication of Cancer by Natural Killer Cells. , 2018, Trends in cancer.

[82]  P. Sharma,et al.  Modulation of EZH2 expression in T cells improves efficacy of anti–CTLA-4 therapy , 2018, The Journal of clinical investigation.

[83]  J. Schlom,et al.  Epigenetic priming of both tumor and NK cells augments antibody-dependent cellular cytotoxicity elicited by the anti-PD-L1 antibody avelumab against multiple carcinoma cell types , 2018, Oncoimmunology.

[84]  S. Tai,et al.  Snail-overexpressing Cancer Cells Promote M2-Like Polarization of Tumor-Associated Macrophages by Delivering MiR-21-Abundant Exosomes , 2018, Neoplasia.

[85]  S. Lowe,et al.  Tumor Cell‐Intrinsic Factors Underlie Heterogeneity of Immune Cell Infiltration and Response to Immunotherapy , 2018, Immunity.

[86]  Jeremy M Boss,et al.  B cell activation and plasma cell differentiation are inhibited by de novo DNA methylation , 2018, Nature Communications.

[87]  Christopher D. Scharer,et al.  The Histone Demethylase LSD1 Regulates B Cell Proliferation and Plasmablast Differentiation , 2018, The Journal of Immunology.

[88]  P. Marcato,et al.  Dying to Be Noticed: Epigenetic Regulation of Immunogenic Cell Death for Cancer Immunotherapy , 2018, Front. Immunol..

[89]  Michael R. Green,et al.  Inhibition of Enhancer of zeste homolog 2 (EZH2) induces natural killer cell-mediated eradication of hepatocellular carcinoma cells , 2018, Proceedings of the National Academy of Sciences.

[90]  P. Wei,et al.  HDAC6 regulates microRNA-27b that suppresses proliferation, promotes apoptosis and target MET in diffuse large B-cell lymphoma , 2018, Leukemia.

[91]  F. Ginhoux,et al.  Developmental Analysis of Bone Marrow Neutrophils Reveals Populations Specialized in Expansion, Trafficking, and Effector Functions , 2018, Immunity.

[92]  Howard Y. Chang,et al.  m6A mRNA methylation sustains Treg suppressive functions , 2018, Cell Research.

[93]  Duonan Yu,et al.  Activating and sustaining c-Myc by depletion of miR-144/451 gene locus contributes to B-lymphomagenesis , 2017, Oncogene.

[94]  C. Zahnow,et al.  Epigenetic therapy activates type I interferon signaling in murine ovarian cancer to reduce immunosuppression and tumor burden , 2017, Proceedings of the National Academy of Sciences.

[95]  Xiu-xia Zhou,et al.  Regulation of RIP3 by the transcription factor Sp1 and the epigenetic regulator UHRF1 modulates cancer cell necroptosis , 2017, Cell Death and Disease.

[96]  I. Feldman,et al.  EZH2 Inhibition by Tazemetostat Results in Altered Dependency on B-cell Activation Signaling in DLBCL , 2017, Molecular Cancer Therapeutics.

[97]  R. Flavell,et al.  The DNA Methylcytosine Dioxygenase Tet2 Sustains Immunosuppressive Function of Tumor‐Infiltrating Myeloid Cells to Promote Melanoma Progression , 2017, Immunity.

[98]  T. Nakayama,et al.  Menin Controls the Memory Th2 Cell Function by Maintaining the Epigenetic Integrity of Th2 Cells , 2017, The Journal of Immunology.

[99]  K. Pienta,et al.  Abstract 4005: HDAC inhibitors regulate M2 tumor-associated macrophage function through histone acetylation , 2017 .

[100]  Paul G. Thomas,et al.  De Novo Epigenetic Programs Inhibit PD-1 Blockade-Mediated T Cell Rejuvenation , 2017, Cell.

[101]  F. Belardelli,et al.  Antitumor Effects of Epidrug/IFNα Combination Driven by Modulated Gene Signatures in Both Colorectal Cancer and Dendritic Cells , 2017, Cancer Immunology Research.

[102]  Steven H. Kleinstein,et al.  Polycomb Repressive Complex 2‐Mediated Chromatin Repression Guides Effector CD8+ T Cell Terminal Differentiation and Loss of Multipotency , 2017, Immunity.

[103]  Jie Yin,et al.  Chromatin state dynamics during NK cell activation , 2017, Oncotarget.

[104]  A. Letai,et al.  Class IIa HDAC inhibition reduces breast tumours and metastases through anti-tumour macrophages , 2017, Nature.

[105]  M. Dyer,et al.  CXCL-8/IL8 Produced by Diffuse Large B-cell Lymphomas Recruits Neutrophils Expressing a Proliferation-Inducing Ligand APRIL. , 2017, Cancer research.

[106]  X. Bai,et al.  IRF8 is the target of SIRT1 for the inflammation response in macrophages , 2017, Innate immunity.

[107]  B. Christensen,et al.  DNA Methylation-Derived Neutrophil-to-Lymphocyte Ratio: An Epigenetic Tool to Explore Cancer Inflammation and Outcomes , 2016, Cancer Epidemiology, Biomarkers & Prevention.

[108]  Todd M. Allen,et al.  The epigenetic landscape of T cell exhaustion , 2016, Science.

[109]  J. Yen,et al.  DNA Methyltransferase Inhibitor Promotes Human CD4+CD25hFOXP3+ Regulatory T Lymphocyte Induction under Suboptimal TCR Stimulation , 2016, Front. Immunol..

[110]  A. Valencia,et al.  Genome-wide analysis of differential transcriptional and epigenetic variability across human immune cell types , 2016, Genome Biology.

[111]  E. Furth,et al.  CXCR2-Dependent Accumulation of Tumor-Associated Neutrophils Regulates T-cell Immunity in Pancreatic Ductal Adenocarcinoma , 2016, Cancer Immunology Research.

[112]  Yueqiu Gao,et al.  MicroRNA-223 ameliorates alcoholic liver injury by inhibiting the IL-6–p47phox–oxidative stress pathway in neutrophils , 2016, Gut.

[113]  S. Leng,et al.  microRNA-155 deficiency impairs dendritic cell function in breast cancer , 2016, Oncoimmunology.

[114]  Peter A. Jones,et al.  Epigenetic Determinants of Cancer. , 2016, Cold Spring Harbor perspectives in biology.

[115]  E. Jaffee,et al.  De novo DNA methylation by DNA methyltransferase 3a controls early effector CD8+ T-cell fate decisions following activation , 2016, Proceedings of the National Academy of Sciences.

[116]  S. Knapp,et al.  Epigenomic regulation of oncogenesis by chromatin remodeling , 2016, Oncogene.

[117]  A. Gomaa,et al.  Enhancing NK cell cytotoxicity by miR-182 in hepatocellular carcinoma. , 2016, Human immunology.

[118]  Stefan Wallner,et al.  Epigenetic dynamics of monocyte-to-macrophage differentiation , 2016, Epigenetics & Chromatin.

[119]  Xia Li,et al.  Methyltransferase Dnmt3a upregulates HDAC9 to deacetylate the kinase TBK1 for activation of antiviral innate immunity , 2016, Nature Immunology.

[120]  K. Rajewsky,et al.  Tissue-specific DNA demethylation is required for proper B-cell differentiation and function , 2016, Proceedings of the National Academy of Sciences.

[121]  M. Biffoni,et al.  IFN-α potentiates the direct and immune-mediated antitumor effects of epigenetic drugs on both metastatic and stem cells of colorectal cancer , 2016, Oncotarget.

[122]  E. Haura,et al.  HDAC Inhibitors Enhance T-Cell Chemokine Expression and Augment Response to PD-1 Immunotherapy in Lung Adenocarcinoma , 2016, Clinical Cancer Research.

[123]  G. Rabinovich,et al.  Satb1 Overexpression Drives Tumor-Promoting Activities in Cancer-Associated Dendritic Cells. , 2016, Cell reports.

[124]  C. Niu,et al.  Epigenetic suppression of the antitumor cytotoxicity of NK cells by histone deacetylase inhibitor valproic acid. , 2016, American journal of cancer research.

[125]  E. Ballestar,et al.  IL-4 orchestrates STAT6-mediated DNA demethylation leading to dendritic cell differentiation , 2016, Genome Biology.

[126]  Kathleen R. Cho,et al.  Epigenetic silencing of Th1 type chemokines shapes tumor immunity and immunotherapy , 2015, Nature.

[127]  K. Basso,et al.  Disruption of KMT2D perturbs germinal center B cell development and promotes lymphomagenesis , 2015, Nature Medicine.

[128]  U. Bogdahn,et al.  Activation of TGF‐β‐induced non‐Smad signaling pathways during Th17 differentiation , 2015, Immunology and cell biology.

[129]  Binqing Fu,et al.  MicroRNA transcriptomes of distinct human NK cell populations identify miR-362-5p as an essential regulator of NK cell function , 2015, Scientific Reports.

[130]  R. Jaenisch,et al.  TET1 is a tumor suppressor of hematopoietic malignancy , 2015, Nature Immunology.

[131]  Yuan Zhang,et al.  MicroRNA-22 Impairs Anti-Tumor Ability of Dendritic Cells by Targeting p38 , 2015, PloS one.

[132]  D. Heo,et al.  MicroRNA-21 plays an oncogenic role by targeting FOXO1 and activating the PI3K/AKT pathway in diffuse large B-cell lymphoma , 2015, Oncotarget.

[133]  P. Delvenne,et al.  Cervical (pre)neoplastic microenvironment promotes the emergence of tolerogenic dendritic cells via RANKL secretion , 2015, Oncoimmunology.

[134]  Y. Huang,et al.  Histone deacetylase inhibitors prevent activation-induced cell death and promote anti-tumor immunity , 2015, Oncogene.

[135]  Tim J. Wigle,et al.  EPZ011989, A Potent, Orally-Available EZH2 Inhibitor with Robust in Vivo Activity , 2015, ACS medicinal chemistry letters.

[136]  M. Ebinger,et al.  Both mature KIR+ and immature KIR- NK cells control pediatric acute B-cell precursor leukemia in NOD.Cg-Prkdcscid IL2rgtmWjl/Sz mice. , 2014, Blood.

[137]  I. Amit,et al.  Tissue-Resident Macrophage Enhancer Landscapes Are Shaped by the Local Microenvironment , 2014, Cell.

[138]  Wei Li,et al.  Dnmt3a and Dnmt3b have overlapping and distinct functions in hematopoietic stem cells. , 2014, Cell stem cell.

[139]  M. Weirauch,et al.  DNA methylation dynamics during ex vivo differentiation and maturation of human dendritic cells , 2014, Epigenetics & Chromatin.

[140]  C. Benner,et al.  Function of a Foxp3 cis-Element in Protecting Regulatory T Cell Identity , 2014, Cell.

[141]  M. Wolter,et al.  MicroRNA-mediated down-regulation of NKG2D ligands contributes to glioma immune escape , 2014, Oncotarget.

[142]  M. Piris,et al.  miR-217 is an oncogene that enhances the germinal center reaction. , 2014, Blood.

[143]  P. Greenberg,et al.  MicroRNA-150 regulates the cytotoxicity of natural killers by targeting perforin-1. , 2014, The Journal of allergy and clinical immunology.

[144]  Hyun-Dong Chang,et al.  NK cells gain higher IFN‐γ competence during terminal differentiation , 2014, European journal of immunology.

[145]  Ming-Ming Zhou,et al.  Writers and readers of histone acetylation: structure, mechanism, and inhibition. , 2014, Cold Spring Harbor perspectives in biology.

[146]  J. Yang,et al.  MicroRNA-19a-3p inhibits breast cancer progression and metastasis by inducing macrophage polarization through downregulated expression of Fra-1 proto-oncogene , 2014, Oncogene.

[147]  K. Toellner,et al.  Germinal center dysregulation by histone methyltransferase EZH2 promotes lymphomagenesis(Journal of Clinical Investigation) , 2014 .

[148]  E. Seto,et al.  Erasers of histone acetylation: the histone deacetylase enzymes. , 2014, Cold Spring Harbor perspectives in biology.

[149]  C. Qian,et al.  miRNomes of haematopoietic stem cells and dendritic cells identify miR-30b as a regulator of Notch1 , 2013, Nature Communications.

[150]  Yutaka Suzuki,et al.  The polycomb protein Ezh2 regulates differentiation and plasticity of CD4(+) T helper type 1 and type 2 cells. , 2013, Immunity.

[151]  V. Nandakumar,et al.  Epigenetic control of natural killer cell maturation by histone H2A deubiquitinase, MYSM1 , 2013, Proceedings of the National Academy of Sciences.

[152]  Eugenia G. Giannopoulou,et al.  Synergistic activation of inflammatory cytokine genes by interferon-γ-induced chromatin remodeling and toll-like receptor signaling. , 2013, Immunity.

[153]  P. Casali,et al.  Epigenetics of the antibody response. , 2013, Trends in immunology.

[154]  O. Elemento,et al.  EZH2 is required for germinal center formation and somatic EZH2 mutations promote lymphoid transformation. , 2013, Cancer cell.

[155]  G. Schotta,et al.  Histone H4 Lysine 20 methylation: key player in epigenetic regulation of genomic integrity , 2013, Nucleic acids research.

[156]  A. Sanz,et al.  DNA demethylation and histone H3K9 acetylation determine the active transcription of the NKG2D gene in human CD8+ T and NK cells , 2013, Epigenetics.

[157]  H. A. Schreiber,et al.  An epigenetic silencing pathway controlling T helper 2 cell lineage commitment , 2012, Nature.

[158]  Li Lin,et al.  Identification of Resting and Type I IFN-Activated Human NK Cell miRNomes Reveals MicroRNA-378 and MicroRNA-30e as Negative Regulators of NK Cell Cytotoxicity , 2012, The Journal of Immunology.

[159]  P. Bhattacharya,et al.  TLR signaling-mediated differential histone modification at IL-10 and IL-12 promoter region leads to functional impairments in tumor-associated macrophages. , 2011, Carcinogenesis.

[160]  P. Greenberg,et al.  Human microRNA-27a* targets Prf1 and GzmB expression to regulate NK-cell cytotoxicity. , 2011, Blood.

[161]  O. Elemento,et al.  DNA methyltransferase 1 and DNA methylation patterning contribute to germinal center B-cell differentiation. , 2011, Blood.

[162]  Raja Jothi,et al.  Genome-wide analyses of transcription factor GATA3-mediated gene regulation in distinct T cell types. , 2011, Immunity.

[163]  Steven J. M. Jones,et al.  Frequent mutation of histone modifying genes in non-Hodgkin lymphoma , 2011, Nature.

[164]  Yi Zhang,et al.  The diverse functions of Dot1 and H3K79 methylation. , 2011, Genes & development.

[165]  Ryan D. Morin,et al.  Somatic mutations at EZH2 Y641 act dominantly through a mechanism of selectively altered PRC2 catalytic activity, to increase H3K27 trimethylation. , 2011, Blood.

[166]  P. Cheung,et al.  Histone code pathway involving H3 S28 phosphorylation and K27 acetylation activates transcription and antagonizes polycomb silencing , 2011, Proceedings of the National Academy of Sciences.

[167]  D. Reinberg,et al.  The Polycomb complex PRC2 and its mark in life , 2011, Nature.

[168]  O. Elemento,et al.  EZH2-mediated epigenetic silencing in germinal center B cells contributes to proliferation and lymphomagenesis. , 2010, Blood.

[169]  R. Copeland,et al.  Coordinated activities of wild-type plus mutant EZH2 drive tumor-associated hypertrimethylation of lysine 27 on histone H3 (H3K27) in human B-cell lymphomas , 2010, Proceedings of the National Academy of Sciences.

[170]  K. Nakai,et al.  The Jmjd3-Irf4 axis regulates M2 macrophage polarization and host responses against helminth infection , 2010, Nature Immunology.

[171]  F. Slack,et al.  OncomiR addiction in an in vivo model of microRNA-21-induced pre-B-cell lymphoma , 2010, Nature.

[172]  M. L. Le Beau,et al.  DNMT3B7, a truncated DNMT3B isoform expressed in human tumors, disrupts embryonic development and accelerates lymphomagenesis. , 2010, Cancer research.

[173]  Jinping Li,et al.  Nonhistone protein acetylation as cancer therapy targets , 2010, Expert review of anticancer therapy.

[174]  J. O’Shea,et al.  Diverse targets of the transcription factor STAT3 contribute to T cell pathogenicity and homeostasis. , 2010, Immunity.

[175]  B. Brüne,et al.  MicroRNA-27b Contributes to Lipopolysaccharide-mediated Peroxisome Proliferator-activated Receptor γ (PPARγ) mRNA Destabilization* , 2010, The Journal of Biological Chemistry.

[176]  C. Croce,et al.  miR-15a and miR-16-1 in cancer: discovery, function and future perspectives , 2010, Cell Death and Differentiation.

[177]  Li-li Wang,et al.  Demethylating treatment suppresses natural killer cell cytolytic activity. , 2009, Molecular immunology.

[178]  Dereje D. Jima,et al.  Patterns of microRNA expression characterize stages of human B-cell differentiation. , 2009, Blood.

[179]  C. Ponting,et al.  Evolution and Functions of Long Noncoding RNAs , 2009, Cell.

[180]  Fabian Model,et al.  Quantitative DNA methylation analysis of FOXP3 as a new method for counting regulatory T cells in peripheral blood and solid tissue. , 2009, Cancer research.

[181]  Robert Tibshirani,et al.  Differentiation stage-specific expression of microRNAs in B lymphocytes and diffuse large B-cell lymphomas. , 2008, Blood.

[182]  Jerry L. Workman,et al.  Crosstalk among Histone Modifications , 2008, Cell.

[183]  Mauro Biffoni,et al.  The miR-15a–miR-16-1 cluster controls prostate cancer by targeting multiple oncogenic activities , 2008, Nature Medicine.

[184]  N. Jonjić,et al.  Correlation of serum IL‐6, IL‐8 and IL‐10 levels with clinicopathological features and prognosis in patients with diffuse large B‐cell lymphoma , 2008, International journal of laboratory hematology.

[185]  Fuping Zhang,et al.  T helper type 1–specific Brg1 recruitment and remodeling of nucleosomes positioned at the IFN-γ promoter are Stat4 dependent , 2006, The Journal of experimental medicine.

[186]  Ali Shilatifard,et al.  Transcriptional activation via sequential histone H2B ubiquitylation and deubiquitylation, mediated by SAGA-associated Ubp8. , 2003, Genes & development.

[187]  D. Gottschling,et al.  The ubiquitin-conjugating enzyme Rad6 (Ubc2) is required for silencing in Saccharomyces cerevisiae , 1997, Molecular and cellular biology.

[188]  M. Sporn,et al.  The combination of the histone deacetylase inhibitor vorinostat and synthetic triterpenoids reduces tumorigenesis in mouse models of cancer. , 2013, Carcinogenesis.

[189]  S. Gordon.  Alternative activation of macrophages , 2003, Nature Reviews Immunology.